Clinical Trial Update: Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety and efficacy study of asfotase alfa in severely affected infants with hypophosphatasia has completed, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypophosphatasia

Drugs mentioned

• Asfotase alfa (asfotase alfa)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hypophosphatasia (HPP) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2011-09-30